Longitudinal analysis of B- and T-cell responses to SARS-CoV-2 recombinant S-protein vaccine S-268019-b in phase 1/2 priming and booster study

Masaya Fujitani, Xiuyuan Lu, Ryo Shinnakasu, Takeshi Inoue, Yujiro Kidani, Naomi M. Seki, Satoru Ishida, Shungo Mitsuki, Takeshi Ishihara, Miwa Aoki, Akio Suzuki, Koji Takahashi, Masahiro Takayama, Takeshi Ota, Satoshi Iwata, Risa Yokokawa Shibata, Takuhiro Sonoyama, Mari Ariyasu, Ayumi Kitano, Tommy Terooatea, Jordan Kelly Villa, Kazuo Yamashita, Sho Yamasaki, Tomohiro Kurosaki, Shinya Omoto
doi: https://doi.org/10.1101/2024.10.01.24314659

Article Information

doi 
https://doi.org/10.1101/2024.10.01.24314659
History 
  • October 3, 2024.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Masaya Fujitani1,10,
  2. Xiuyuan Lu2,10,
  3. Ryo Shinnakasu3,10,
  4. Takeshi Inoue3,
  5. Yujiro Kidani1,
  6. Naomi M. Seki1,
  7. Satoru Ishida1,
  8. Shungo Mitsuki1,
  9. Takeshi Ishihara1,
  10. Miwa Aoki1,
  11. Akio Suzuki1,
  12. Koji Takahashi1,
  13. Masahiro Takayama4,
  14. Takeshi Ota4,
  15. Satoshi Iwata5,
  16. Risa Yokokawa Shibata6,
  17. Takuhiro Sonoyama6,
  18. Mari Ariyasu6,
  19. Ayumi Kitano7,
  20. Tommy Terooatea7,
  21. Jordan Kelly Villa7,
  22. Kazuo Yamashita7,
  23. Sho Yamasaki2,8,9,*,
  24. Tomohiro Kurosaki3,9,* and
  25. Shinya Omoto1,11,*
  1. 1Vaccine Business Division, Shionogi & Co., Ltd., Osaka, Japan
  2. 2Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan
  3. 3Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan
  4. 4Pharmaceutical Technology Research Division, Shionogi & Co., Ltd., Osaka, Japan
  5. 5Department of Microbiology, Tokyo Medical University, Tokyo, Japan
  6. 6Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
  7. 7KOTAI Biotechnologies, Inc., Osaka, Japan
  8. 8Department of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan
  9. 9Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Osaka, Japan
  1. ↵*Corresponding authors: Shinya Omoto (lead contact)
    , Shionogi Pharmaceutical Research Center, 3-1-1, Futaba-cho, Toyonaka, Osaka 561-0825, Japan, Contact number: +81-70-4397-2561, Email ID: shinya.oomoto{at}shionogi.co.jp; Sho Yamasaki
    , Osaka University, IFReC Research Building, Osaka University 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan Contact number: +81-6-6879-8306, Email ID: yamasaki{at}biken.osaka-u.ac.jp; Tomohiro Kurosaki
    , Osaka University, IFReC Research Building, Osaka University 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan Contact number: +81-6-6879-4457, Email ID: kurosaki{at}ifrec.osaka-u.ac.jp

  1. ↵10 These authors contributed equally.

Back to top
Posted October 03, 2024.
Download PDF

Supplementary Material

Data/Code
Email
Longitudinal analysis of B- and T-cell responses to SARS-CoV-2 recombinant S-protein vaccine S-268019-b in phase 1/2 priming and booster study
Masaya Fujitani, Xiuyuan Lu, Ryo Shinnakasu, Takeshi Inoue, Yujiro Kidani, Naomi M. Seki, Satoru Ishida, Shungo Mitsuki, Takeshi Ishihara, Miwa Aoki, Akio Suzuki, Koji Takahashi, Masahiro Takayama, Takeshi Ota, Satoshi Iwata, Risa Yokokawa Shibata, Takuhiro Sonoyama, Mari Ariyasu, Ayumi Kitano, Tommy Terooatea, Jordan Kelly Villa, Kazuo Yamashita, Sho Yamasaki, Tomohiro Kurosaki, Shinya Omoto
medRxiv 2024.10.01.24314659; doi: https://doi.org/10.1101/2024.10.01.24314659
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area